DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier

Servier agreed to acquire Day One for $21.50 per share in a $2.5B deal, sending Day One's stock up ~66%. The acquisition adds brain tumor drug Ojemda and other oncology pipeline assets to Servier's portfolio. The deal represents a significant premium to the prior market price and materially changes Day One's valuation and strategic outlook.

Analysis

Servier agreed to acquire Day One for $21.50 per share in a $2.5B deal, sending Day One's stock up ~66%. The acquisition adds brain tumor drug Ojemda and other oncology pipeline assets to Servier's portfolio. The deal represents a significant premium to the prior market price and materially changes Day One's valuation and strategic outlook.